The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior? (Q27030892)

highly active antiretroviral therapy

19 September 2019

2 references

22 January 2021

26 January 2021

Andrew Carr

1

1 reference

Jennifer Hoy

series ordinal

2

1 reference

Anton Pozniak

series ordinal

3

1 reference

language of work or name

1 reference

2012

1 reference

17 July 2012

4 references

25 June 2019

19 September 2019

22 January 2021

26 January 2021

5 references

25 June 2019

19 September 2019

22 January 2021

26 January 2021

9

1 reference

issue

7

1 reference

page(s)

e1001240

1 reference

Creative Commons Attribution 4.0 International

copyright license

4 references

25 June 2019

19 September 2019

22 January 2021

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine

26 January 2021

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398965

Efficacy and tolerability of initial antiretroviral therapy: a systematic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398965

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398965

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

28 September 2017

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001240

TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001240

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001240

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001240

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001240

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001240

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001240

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398965

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects (revised October 7, 2000).

28 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/22815652

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PMED.1001240

0 references

1 reference

PubMed publication ID

22815652

1 reference